Breaking News

Evonik Begins Construction of $220M U.S. Facility for Pharmaceutical Lipids

Facility to secure global supply of functional excipients for RNA medicines.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Evonik began construction of its $220 million global-scale production facility for pharmaceutical specialty lipids in Lafayette, IN. The new facility is expected to secure the industry’s access to critical excipients needed for mRNA vaccines and other nucleic acid therapies. The plant is scheduled to go onstream in 2025.   “Our new Lipid Innovation Center will secure the health innovations of tomorrow. Through this investment, we reinforce our leading position in the pharmaceutical industry. W...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters